Oncolytic virotherapy is a novel strategy using viruses, either naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed. The destruction of cancer cells occurs either through direct lytic rupture by multi-cycle viral replication or the subsequent induction of apoptosis and successful application of virotherapy requires preferential and efficient amplification of the virus to kill cancer cells. PRORVLYSIN® is a new class of potent genetically engineered common cold-like virus that selectively kills prostate cancer cells, but not normal healthy cells. With this medical breakthrough will potentially help millions of people worldwide in the fight against prostate cancers. Thus, PRORVLYSIN® is vastly safer to use and easier to process, as compared to traditional chemo- or radio-therapies of tumors, allowing patients to enjoy a much higher quality of life during treatment.
PRORVLYSIN® therapy may cause common cold-like symptoms such as chills, fever, muscle aches, headache, and weakness, loss of appetite, nausea, vomiting, or diarrhea. Patients may also experience other side effects including the tendency to bleed or bruise easily, and some get a rash. Home treatment to ease symptoms and prevent complications is usually all that is needed. Some of these problems may be severe, but they go away after the treatment stops.